Kyverna Therapeutics, Inc.
KYTX
Positions held
Your positionsKYTX isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $382.19M | Enterprise value | $215.76M | Trailing P/E | — | Forward P/E | -1.95 |
| PEG | — | Price / book | 2.30 | Beta | 2.06 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -87.2% | ROA | -44.5% | Debt / equity | 0.20 |
| Current ratio | 9.06 | Free cash flow | -$107.68M | Analyst recommendation | strong_buy | Mean target | $30.40 |
| 52w high | $13.67 | 52w low | $5.96 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — | — |
| Net income | -$38.3M | -$39.7M | -$37.8M | -$36.8M | -$42.1M |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$39.6M | -$41.4M | -$39.3M | -$38.7M | -$44.4M |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $7.0M |
| Op margin | — | — | — | -418.3% |
| Net income | -$161M | -$127M | -$60.4M | -$28.9M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$170M | -$143M | -$62.4M | -$29.4M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-05 · BioMarin Appoints Cara Bauer as Chief People Officer
2026-09-24 · Kyverna stock jumps on positive one-year therapy data
2026-09-24 · Kyverna Reports One-Year Miv-Cel Data From SPS and gMG Trials
2026-09-02 · Kyverna Therapeutics to Present at Upcoming Investor Conferences
2026-09-02 · Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts
2026-08-11 · Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results
2026-07-27 · Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel
Price (daily)
Full chart · RSI · MACD · patterns